Screener
Corvus Pharmaceuticals CRVS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock: $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; 0 shares issued and outstanding at each of March 31, 2026 and December 31, 2025 | — | — |
| Common stock: $0.0001 par value; 290,000,000 shares authorized at March 31, 2026 and December 31, 2025; 84,090,424 and 74,696,629 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 8 | 7 |
| Additional paid-in capital | 667,782 | 474,387 |
| Accumulated other comprehensive loss | (1,126) | (896) |
| Accumulated deficit | (425,985) | (412,293) |
| Total stockholders’ equity | 240,679 | 61,205 |
| Total liabilities and stockholders’ equity | $253,195 | $71,119 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's retained earnings?
- Corvus Pharmaceuticals (CRVS) reported retained earnings of -$425.99M in Q1 2026.
- How has Corvus Pharmaceuticals's retained earnings changed year-over-year?
- Corvus Pharmaceuticals's retained earnings decreased by 11.6% year-over-year, from -$381.82M to -$425.99M.
- What is the long-term trend for Corvus Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's retained earnings has grown at a 13.1% compound annual growth rate (CAGR), from -$223.14M to -$412.29M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Corvus Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude